Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998 for Incyte Pharmaceuticals, Inc. (Incyte). The Company designs and markets genomic database products, software tools, and gene expression microarray services to the pharmaceutical and biotechnology industries. A significant event during this period was the January 1998 acquisition of Synteni, Inc., a microarray-based gene expression company, accounted for as a pooling-of-interests. Consequently, all prior financial data presented has been restated to include Synteni's operations.
Key Financial Metrics
| Metric (in thousands) | Q1 1998 | Q1 1997 |
|---|---|---|
| Revenues | $30,379 | $17,998 |
| Net Income | $3,566 | $457 |
| Diluted EPS | $0.12 | $0.02 |
| Operating Cash Flow | $31,665 | $8,335 |
| Cash & Cash Equivalents | $42,726 | $10,252 |
| Total Cash, Equivalents & Marketable Securities | $132,439 | $N/A |
| Long-Term Debt | $626 | $N/A |
| Accumulated Deficit | ($28,307) | ($31,873) |
Note: Q1 1997 figures are restated to reflect the Synteni acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 69% to $30.4 million, driven primarily by new and expanded database collaboration agreements.
- Profitability: Net income surged to $3.6 million from $0.5 million. Operating income improved to $2.9 million from $12,000.
- Expense Increases: Total costs and expenses rose to $27.5 million. Research and Development (R&D) expenses increased to $21.7 million due to expanded bioinformatics, microarray production, and Synteni integration. Selling, General, and Administrative (SG&A) expenses rose to $4.6 million.
- Acquisition Charges: The Company recorded $1.2 million in acquisition-related charges for the Synteni merger.
- Joint Venture Losses: The Company recognized a $0.6 million loss from its 50% interest in diaDexus, LLC, a joint venture formed in September 1997. No such loss was recorded in the prior year period.
- Liquidity: Cash provided by operating activities increased significantly to $31.7 million, aided by a decrease in accounts receivable and an increase in deferred revenue. However, investing activities consumed $46.5 million, primarily for marketable securities and capital expenditures.
Guidance, Outlook, and Risks
- Outlook: Management expects expenses to increase in 1998 due to investments in new product development, microarray capacity, and marketing. The Company believes existing cash resources ($132.4 million in liquid assets) are adequate to fund operations through 1998.
- Capital Needs: The Company is constructing a new 95,000 square foot facility adjacent to its Palo Alto headquarters, with tenant improvement costs estimated between $10.0 million and $15.0 million. Expenses for this facility are not expected until late 1998 or early 1999.
- Profitability Uncertainty: While the Company has reported net income for five consecutive quarters, management cautions that future profitability is not assured. Revenue depends heavily on retaining and acquiring database collaborators, and the Company has significant fixed costs.
- Legal Contingency: On January 6, 1998, Affymetrix, Inc. filed a lawsuit alleging willful infringement of U.S. Patent No. 5,445,934 regarding high-density arrays. Affymetrix seeks a permanent injunction and trebled damages. Incyte intends to defend vigorously, but the outcome is uncertain and could result in substantial expenses.
- Investment Risks: The Company holds equity investments in joint ventures (e.g., diaDexus) and other entities (e.g., OncorMed). OncorMed's auditors expressed substantial doubt regarding its ability to continue as a going concern. The Company evaluates these investments for impairment quarterly.
Investor Verification Checklist
- Patent Litigation Status: Verify the current status of the Affymetrix lawsuit and potential financial exposure regarding the '934 Patent.
- Collaborator Retention: Assess the renewal rates of database collaboration agreements, which are typically three-year terms and critical to revenue stability.
- Synteni Integration: Monitor the ability to secure high-volume customers for Synteni's microarray services, as prior agreements were primarily small-volume pilots.
- Joint Venture Performance: Review the financial health of diaDexus and OncorMed to assess potential future impairment charges or equity losses.
- Capital Expenditure Timeline: Confirm the schedule and cost overruns related to the new facility construction and data processing hardware investments.